Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 8:2011:270149.
doi: 10.4061/2011/270149.

Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases

Toral P Kobawala  1 , Girish H Patel, Dhara R Gajjar, Kamini N Patel, Premal B Thakor, Urvi B Parekh, Kirti M Patel, Shilin N Shukla, Pankaj M Shah
Affiliations

Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases

Toral P Kobawala et al. J Thyroid Res. .

Abstract

Serum interleukin-8 (IL-8) and interferon-alpha (IFN-α) levels have been estimated from a total of 88 individuals of which 19 were disease-free healthy individuals, and 69 were patients with thyroid diseases: goitre (N = 21), autoimmune diseases (N = 16), and carcinomas (N = 32). Both IL-8 and IFN-α were significantly higher in all the patients as compared to healthy individuals. Serum IL-8 levels showed significant positive correlation with disease stage in thyroid cancer patients. Higher serum IL-8 levels were associated with advanced disease stage while no significant correlation was observed between serum IFN-α levels and any of the clinicopathological parameters. IL-8 and IFN-α significantly correlated with each other in anaplastic carcinoma patients. Finally concluding, monitoring the serum IL-8 and IFN-α levels can help differentiate patients with thyroid diseases from healthy individuals, and IL-8 seems to have a role in the pathogenesis of thyroid diseases and may represent a target for innovative diagnostic and therapeutic strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC curves for IL-8 and IFN-α.
Figure 1
Figure 1
ROC curves for IL-8 and IFN-α.
Figure 2
Figure 2
(a) Incidence of IL-8 and IFN-α levels in patients with thyroid diseases as compared to healthy individuals. (b) Incidence of IL-8 and IFN-α levels in thyroid carcinoma patients as compared to healthy individuals. (c) Incidence of IL-8 and IFN-α levels in early- and advanced-stage thyroid carcinoma patients as compared to healthy individuals.
Figure 3
Figure 3
Association between serum IL-8 levels and histopathological stage of thyroid carcinoma patients.
Figure 4
Figure 4
Relative risk of IL-8 in early- and advanced-stage thyroid carcinoma patients.
See this image and copyright information in PMC

References

    1. http://www.endocrinologist.com/thyroid.htm.
    1. Blesa JMG, Pulido EG, Pulla MP, et al. Old and new insights in the treatment of thyroid carcinoma. Journal of Thyroid Research. 2010;2010:16 pages. Article ID 279468. - PMC - PubMed
    1. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66(2):321–330. - PubMed
    1. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma: a study of 70 cases. American Journal of Clinical Pathology. 1985;83(2):135–158. - PubMed
    1. Ron E. Epidemiology of thyroid cancer. In: Schottenfeld D, Fraumeni JR Jr., editors. Cancer Epidemiology and Prevention. Oxford, UK: Oxford University Press; 1996. pp. 1000–1021.

LinkOut - more resources